Wordt geladen...
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...
Bewaard in:
| Gepubliceerd in: | Ther Clin Risk Manag |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4644179/ https://ncbi.nlm.nih.gov/pubmed/26609233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S72943 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|